Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Haemodialysis With Secondary Hyperparathyroidism

Trial Profile

Comparison of Efficacy and Safety of Paricalcitol Injection With Maxacalcitol Injection in Adult Japanese Chronic Kidney Disease Subjects Receiving Haemodialysis With Secondary Hyperparathyroidism

Completed
Phase of Trial: Phase III

Latest Information Update: 20 May 2016

At a glance

  • Drugs Paricalcitol (Primary) ; Maxacalcitol
  • Indications Secondary hyperparathyroidism
  • Focus Registrational; Therapeutic Use
  • Sponsors Abbott Japan; AbbVie
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 19 Jun 2014 New trial record
    • 24 Apr 2012
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top